Disc Medicine (IRON) Receives a Buy from Cantor Fitzgerald
Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on Disc Medicine on February 13 and set a price target of $125.00. The company’s shares closed last Friday at $55.95.
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Kluska is a 5-star analyst with an average return of 26.3% and a 48.48% success rate. Kluska covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, DBV Technologies SA – American, and Mereo Biopharma Group Plc.
In addition to Cantor Fitzgerald, Disc Medicine also received a Buy from Truist Financial’s Danielle Brill in a report issued today. However, on February 4, TipRanks – OpenAI reiterated a Hold rating on Disc Medicine (NASDAQ: IRON).
Based on Disc Medicine’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $62.32 million. In comparison, last year the company had a GAAP net loss of $26.6 million
Based on the recent corporate insider activity of 54 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IRON in relation to earlier this year. Most recently, in December 2025, Kevin Bitterman, a Director at IRON sold 754.00 shares for a total of $68,968.38.
Read More on IRON:
Disclaimer & DisclosureReport an Issue
- Disc Medicine: Long‑Term Value Intact as Bitopertin Shifts to Lower‑Risk Traditional Approval Path
- Disc Medicine move down Friday ‘fair’ after bitopertin CRL, says Wells Fargo
- Disc Medicine Receives FDA Complete Response on Bitopertin
- Disc Medicine off lows after saying FDA issue ‘readily addressable’
- Disc Medicine down 32% to $49 after confirming rejection letter from FDA
